Case reportTwo siblings with limb-girdle muscular dystrophy type 2E responsive to DEFLAZACORT (cas 13649-88-2)

Add time:09/26/2019    Source:sciencedirect.com

Two siblings were evaluated for progressive proximal weakness and elevated creatine kinase. Immunohistochemical staining in the brother’s muscle biopsy showed near absence of all four sarcoglycan subunits. Clinical progression prompted a trial of deflazacort in both siblings. At 22 months of drug therapy, both patients have stable or improved strength testing. Further analysis on the muscle biopsy revealed homozygous β-sarcoglycan gene mutation (S114F), consistent with the limb-girdle muscular dystrophy type 2E (LGME 2E). Despite the severe phenotype, deflazacort has a beneficial effect on slowing disease progression in LGME 2E similar to that seen in Duchenne muscular dystrophy.

We also recommend Trading Suppliers and Manufacturers of DEFLAZACORT (cas 13649-88-2). Pls Click Website Link as below: cas 13649-88-2 suppliers

Prev:Case ReportToxic epidermal necrolysis associated with DEFLAZACORT (cas 13649-88-2) therapy with nephrotic syndrome
Next:Gallic acid, a natural polyphenol, protects against tert-butyl hydroperoxide- induced hepatotoxicity by activating ERK-Nrf2-Keap1-mediated antioxidative response)